Literature DB >> 15636433

Long-term efficacy of doxazosin plus atenolol in the management of severe and sustained arterial hypertension and reversibility of the cardiac damage induced by chronic cathecolamine excess. A case report in a young girl with recurrent, functioning paraganglioma.

M Pulcrano1, E A Palmieri, L Pagano, L Tauchmanova, A Rossi, S Fazio, G Lombardi, B Biondi.   

Abstract

Herein we report on a young girl with recurrent, functioning paraganglioma of the organ of Zuckerkandl and severe and sustained arterial hypertension (systolic pressure >200, diastolic pressure >120 mmHg); with evidence of cardiac damage induced by chronic cathecolamine excess. She promptly and steadily improved after the institution of doxazosin (6 mg/day) plus atenolol (50 mg bid) treatment. This case demonstrates that a correct therapeutic strategy in the long-term management of patients with inoperable catecholamine-producing neuroendocrine tumors (pheochromocytomas and paragangliomas) can maintain arterial pressure in the normal range and reverse the cardiac damage induced by chronic cathecolamine excess.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15636433     DOI: 10.1007/BF03347522

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

1.  Pheochromocytoma: new concepts and future trends.

Authors:  E L Bravo
Journal:  Kidney Int       Date:  1991-09       Impact factor: 10.612

2.  The preoperative management of phaeochromocytoma.

Authors:  W J Russell; I R Metcalfe; A L Tonkin; D B Frewin
Journal:  Anaesth Intensive Care       Date:  1998-04       Impact factor: 1.669

Review 3.  Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.

Authors:  E L Bravo
Journal:  Endocr Rev       Date:  1994-06       Impact factor: 19.871

Review 4.  Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.

Authors:  K Pacak; W M Linehan; G Eisenhofer; M M Walther; D S Goldstein
Journal:  Ann Intern Med       Date:  2001-02-20       Impact factor: 25.391

5.  Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients.

Authors:  D Erickson; Y C Kudva; M J Ebersold; G B Thompson; C S Grant; J A van Heerden; W F Young
Journal:  J Clin Endocrinol Metab       Date:  2001-11       Impact factor: 5.958

6.  Pheochromocytoma: state-of-the-art and future prospects.

Authors:  Emmanuel L Bravo; Rodrigo Tagle
Journal:  Endocr Rev       Date:  2003-08       Impact factor: 19.871

Review 7.  Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.

Authors:  C A Hoefnagel
Journal:  Eur J Nucl Med       Date:  1994-06

Review 8.  Efficacy of doxazosin in specific hypertensive patient groups.

Authors:  S H Taylor
Journal:  Am Heart J       Date:  1991-01       Impact factor: 4.749

9.  Scintigraphic localization of pheochromocytoma.

Authors:  J C Sisson; M S Frager; T W Valk; M D Gross; D P Swanson; D M Wieland; M C Tobes; W H Beierwaltes; N W Thompson
Journal:  N Engl J Med       Date:  1981-07-02       Impact factor: 91.245

10.  Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma.

Authors:  Cedric Prys-Roberts; John R Farndon
Journal:  World J Surg       Date:  2002-06-19       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.